.webp)
The first BioAgent, Aubrai, is launching today on the Bio Launchpad: https://app.bio.xyz/agents/aubrai
Aubrai is a decentralized scientific AI agent designed to accelerate longevity science through open, incentive-aligned coordination between researchers and citizen scientists. Co-developed by VitaDAO and Bio Protocol, Aubrai is trained on the unpublished lab data of longevity scientist Aubrey de Grey as well as knowledge collected from researchers worldwide via social media, messaging platforms and the Aubrai terminal.
As an onchain AI co-scientist, Aubrai can generate and validate hypotheses, design wet-lab experiments and encrypt scientific data, enriching research outputs while protecting trade secrets.
AI-driven biology is experiencing explosive growth, with giants like Google and OpenAI building scientific agents capable of reading papers and generating hypotheses. But these tools remain siloed in Web2 - disconnected from capital, coordination and shared knowledge. Aubrai breaks these barriers by integrating scientific AI with onchain features for data sharing, continuous funding and discovery monetization, directly engaging the global longevity community.
.webp)
How to Use Aubrai
You can now prompt Aubrai on X by tagging @Aubrai_. The agent is designed to answer a range of questions - from complex scientific inquiries to general health hacks.
Valid hypotheses generated by Aubrai are hashed on Base through Molecule's Proof-of-Invention (POI). This creates a blockchain-verified trail of scientific progress, enabling value and recognition from breakthroughs to flow upstream to contributors whose early insights or negative results paved the way for later discoveries.
View the Aubrai dashboard for tracking hypotheses generated, knowledge ingested, IP-NFTs and other agent analytics. The Aubrai Researcher Terminal is currently in Private Beta, with verified researchers including those with .edu emails getting expedited access. Sign up for Beta access.
Aubrai can utilize funding from $AUBRAI trading fees to bootstrap experiments, and eventually tokenize validated data as onchain knowledge assets known as IP-Tokens.
RMR2 Study
.webp)
Aubrai is trained on cutting-edge research from Dr. de Grey’s lab, LEV Foundation, including the Robust Mouse Rejuvenation (RMR2) project, a comprehensive study testing rejuvenation therapy combinations to achieve lifespan extension in mice. If successful, it could be aging's "AlphaFold moment": a proof that multi‑target rejuvenation works and is worth scaling.
Findings from the RMR2 study will be fed directly into Aubrai’s knowledge graph, continuously enriching the agent with the latest insights from LEV.
The $AUBRAI Token
The AUBRAI token, live on Base initially, can be purchased on the Bio Launchpad: https://app.bio.xyz/agents/aubrai
AUBRAI token holders become permanent stakeholders in Aubrai’s knowledge stream, governing research funding and receiving value from knowledge assets generated by the agent. Aubrai generates revenue by providing insights, compounds and services to pharma companies, consumers and other scientific organizations.
AUBRAI Ignition Sale
The AUBRAI Ignition Sale occurs for 24 hours starting on August 25, 2025, prior to the token going live for open-market trading. You must be holding both BIO tokens and
BioXP ("Bio Experiment Points") to participate in Ignition Sales.
Details:
- The sale lasts 24 hours on the Bio Launchpad.
- During the sale, pledge BioXP and commit BIO to qualify for an allocation.
- Your allocation will be determined following the 24h period based on your pledged BioXP relative to the total pledged BioXP.
- As long as you pledge BioXP in the sale period, you'll be eligible for an allocation.
- FDV is set at ~$269K during the sale; after the sale, AUBRAI is expected to list on an AMM at ~$896K FDV.
- Allocations are capped at 0.5% of the total supply, with any unused BioXP or BIO returned to users after the sale.
- $AUBRAI will go live for open-market trading within hours of the sale closing.
- To disincentivize short-term flipping, if you are allocated tokens in the launch and sell a majority of them within the first two weeks, your ability to earn new BioXP to use on future Ignition Sales is paused for the following three weeks.
More details on Bio Ignition Sales in our docs.
AUBRAI Distribution:
- Total AUBRAI supply: 2,000,000
- Ignition Sale: 20%
- Liquidity Pool: 6%
- Treasury: 15%
- Initial Funders: 20.1%
- LEVF: 10%
- VitaDAO: 22%
- Bio Protocol: 6.9%
'Initial Funders’ refers to investors who funded the start-up costs of one of Aubrai’s underlying research projects, the RMR2 project. These tokens were purchased at roughly 10x above the listing price, or at ~2.5M FDV. 50% of these tokens vest over 4 years, 50% are liquid at the time of TGE.
More details on AUBRAI tokenomics and supply schedule can be found here: https://app.bio.xyz/agents/aubrai
Built on BioAgents
The launch of Aubrai marks the debut of Bio Protocol’s BioAgent model– onchain AI agents that automate complex scientific knowledge work and represent the expertise of scientists and their labs.
The BioAgent system is integrated with leading AI and DeSci protocols:
- Prime Intellect for distributed computing
- ResearchHub for open scientific publishing
- elizaOS for autonomous agent interactions; and
- Pump Science for wet-lab submissions
- Web2 and open-source AI & research platforms, including OpenScholar, HuggingFace & more.
More BioAgents will soon be deployed by BioDAOs and in partnership with top researchers in their fields across an array of scientific domains and operations.
Learn more about the BioAgent stack in Bio’s docs, track upcoming projects on the Bio launchpad, and view the open-source BioAgent code on Github.
Scaling Longevity Intelligence
Dr. Aubrey de Grey said: “Aubrai represents a radical new way to scale collective scientific intelligence. By fusing my team’s expertise with decentralized AI and the wisdom of the global longevity community, we're creating something unprecedented – a scientific AI agent that doesn't just process information, but actively helps researchers turn discoveries into real-world therapeutics.”
Bio plans to expand the BioAgent framework to other prominent researchers and labs, effectively allowing scientists to tokenize and “agentify” their life’s work. Both the researchers interacting with each BioAgent and the agent’s token holders stand to benefit from knowledge growth and appreciation of the agent’s contribution to scientific understanding.
Just as Substack gave content creators the ability to build and monetize audiences outside traditional media, Bio’s infrastructure can turn scientists into the next great creator economy, building and monetizing their research outside traditional pharma structures.
